` INDOCO (Indoco Remedies Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

INDOCO
vs
BSE Sensex 30

Over the past 12 months, INDOCO has underperformed BSE Sensex 30, delivering a return of -32% compared to the BSE Sensex 30's 2% growth.

Stocks Performance
INDOCO vs BSE Sensex 30

Loading
INDOCO
BSE Sensex 30
Add Stock

Performance Gap
INDOCO vs BSE Sensex 30

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
INDOCO vs BSE Sensex 30

Loading
INDOCO
BSE Sensex 30
Add Stock

Competitors Performance
Indoco Remedies Ltd vs Peers

BSE Sensex 30
INDOCO
LLY
JNJ
NOVO B
ROG
Add Stock

Indoco Remedies Ltd
Glance View

Market Cap
21.3B INR
Industry
Pharmaceuticals

Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-01-07. The firm is an integrated, research-oriented pharma company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm's geographical segments include India and Outside India. The firm has nine domestic marketing divisions with a brand portfolio in various therapeutic segments, including Gastrointestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management and Gyneacology. The Company’s brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cal-Aid, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM and Methycal.

INDOCO Intrinsic Value
HIDDEN
Show
Back to Top